Reagent Adapters Supplies
Closed Pre-Solicitation Posted
A newer special notice was posted. See the latest special notice from .
- Solicitation number
- HT942524R0035
- Agency
- Defense Health Agency Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Silver Spring, Maryland 20910, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency is seeking information on commercial reagents and adapters that meet requirements for use in whole genome sequencing. Responses to the Request for Information are due by January 26, 2024 and must be submitted electronically, with capabilities statements not exceeding three pages addressing products that provide 384 unique dual indexes to mitigate index hopping, support up to 1,536 unique indexes, include predesigned balanced sequences for Illumina sequencers, enable GMP ISO 13485 grade manufacturing for clinical research applications, and use state-of-the-art purification methods for next generation sequencing adapters. Quality control testing is required to ensure new batches meet sequencing requirements, with questions due to the contact by the response deadline.
There is no set-aside designation for this opportunity. Responses should be submitted under NAICS code 334516 addressing items under PSC code 6515, with the Defense Health Agency seeking reagents and adapters to support whole genome sequencing requirements without specifying potential incumbents, budget ranges, or anticipated contract values or timelines.
Notice text
Request for Information (RFI)
Reagent Adapters Supplies
General Information:
This is an RFI as defined in FAR 15.201(e) to ascertain whether a commercial item exists that provides the capabilities described herein.
This RFI is issued solely for information and planning purposes and does not constitute a solicitation. All information received in response to this RFI will be treated as business confidential information. Nonetheless, submitters should properly mark their responses if the information is confidential. Responses to the RFI will not be returned. Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expense associated with responding to this RFI.
RFI Response and due date: 26 January 2024
Instructions to Responders:
Responses from all capable and qualified sources are encouraged to respond to this request.
White papers should adhere to the following formatting and outline instructions:
1. All submissions shall be made electronically and be in one of the following formats: Microsoft Word or Adobe PDF.
2. Cover Page (1page) • Title • Organization • Responders technical and administrative points of contact (names, addresses, phone, fax number and email addresses) • Topic area(s) addressed • NAICS Code
3. Interested parties are asked to respond to this RFI and submit a capabilities statement that supports the focus of this RFI as detailed below. Please review the place of performance requirements. Please submit written responses via email in Microsoft Office 2000 or 2007 format. All responses should be complete: in 12-point font; and not to exceed 3 pages total, including graphics, tables, and appendices.
No hardcopies shall be accepted. No written solicitation document is available at this time. Telephone requests will not be honored, and no bidders list shall be maintained. No inquiries regarding any potential future acquisition activities shall be entertained.
Potential offerors are requested to direct all questions via email to the Point of Contact listed below. Responses are due to the Point of Contact, Mr. Nathaniel Reus at email: nathaniel.a.reus.civ@health.mil no later than 11:00AM ET, 26 Jan 2024
Requirement & Specification:
Consumables for use in Whole Genome Sequencers to be delivered under this contract shall meet the following minimum essential characteristics:
- Contractor shall provide a set of 384 full length Y adapter Unique Dual Indexes (UDIs) designed to mitigate errors introduced by index-hopping.
- Contractor shall have the ability to provide a multiplex capacity of up to 1536 unique indexes.
- Contractor shall have available predesigned sequences balanced to prevent GC bias and color-balanced for 2- and 4-color Illumina sequencers.
- Contractor shall have the ability to implement GMP ISO 13485 grade adapter manufacturing practices for clinical research applications.
- Contractor shall implement a manufacturing process that uses state-of-the-art synthesis, purification methods, designed specifically for NGS adapters.
- Contractor shall perform quality control, such as a functional NGS testing, on each new batch of stocked adapter and indexing primer products to ensure the new batch of adapters and primers produce sequencing libraries that meet MRSN sequencing requirements.
Attachments
| File | Type | Posted |
|---|---|---|
| Request for Information WRAIR.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Reagent Adapter Supplies, WRAIR | Special Notice | |
| Reagent Adapters Supplies, WRAIR | Special Notice | |
| Reagent Adapters Supplies | Pre-Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity